Ameritas Advisory Services LLC Has $2.98 Million Stock Holdings in Johnson & Johnson (NYSE:JNJ)

Ameritas Advisory Services LLC reduced its holdings in Johnson & Johnson (NYSE:JNJ - Free Report) by 8.9% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 20,590 shares of the company's stock after selling 2,014 shares during the quarter. Ameritas Advisory Services LLC's holdings in Johnson & Johnson were worth $2,978,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors also recently made changes to their positions in JNJ. IFS Advisors LLC grew its position in Johnson & Johnson by 138.9% during the fourth quarter. IFS Advisors LLC now owns 172 shares of the company's stock worth $25,000 after buying an additional 100 shares in the last quarter. Highline Wealth Partners LLC acquired a new stake in Johnson & Johnson during the third quarter worth about $31,000. RPg Family Wealth Advisory LLC acquired a new stake in Johnson & Johnson during the third quarter worth about $35,000. Mowery & Schoenfeld Wealth Management LLC grew its position in Johnson & Johnson by 58.7% during the third quarter. Mowery & Schoenfeld Wealth Management LLC now owns 246 shares of the company's stock worth $40,000 after buying an additional 91 shares in the last quarter. Finally, Activest Wealth Management acquired a new stake in Johnson & Johnson during the third quarter worth about $40,000. 69.55% of the stock is owned by institutional investors and hedge funds.

Johnson & Johnson Price Performance

Shares of NYSE:JNJ traded down $0.74 during trading on Monday, reaching $147.03. The stock had a trading volume of 10,678,393 shares, compared to its average volume of 6,880,262. Johnson & Johnson has a 52 week low of $140.68 and a 52 week high of $168.85. The business's 50-day moving average price is $148.51 and its 200 day moving average price is $156.10. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.03 and a quick ratio of 0.79. The stock has a market capitalization of $353.99 billion, a PE ratio of 21.28, a P/E/G ratio of 2.30 and a beta of 0.51.

Johnson & Johnson Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 4th. Investors of record on Tuesday, February 18th will be given a $1.24 dividend. This represents a $4.96 annualized dividend and a yield of 3.37%. The ex-dividend date of this dividend is Tuesday, February 18th. Johnson & Johnson's dividend payout ratio (DPR) is presently 71.78%.

Insider Buying and Selling

In related news, Director Mark A. Weinberger acquired 1,000 shares of the company's stock in a transaction that occurred on Thursday, December 12th. The stock was purchased at an average price of $147.22 per share, for a total transaction of $147,220.00. Following the transaction, the director now directly owns 1,000 shares of the company's stock, valued at approximately $147,220. This trade represents a ∞ increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available at this hyperlink. 0.16% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on the company. Citigroup decreased their target price on Johnson & Johnson from $185.00 to $175.00 and set a "buy" rating on the stock in a research report on Wednesday, December 11th. Cantor Fitzgerald restated an "overweight" rating and set a $215.00 price target on shares of Johnson & Johnson in a research note on Wednesday, October 16th. StockNews.com cut shares of Johnson & Johnson from a "strong-buy" rating to a "buy" rating in a research note on Friday. Wolfe Research started coverage on shares of Johnson & Johnson in a research note on Friday, November 15th. They set an "outperform" rating and a $190.00 price target for the company. Finally, Wells Fargo & Company raised their price target on shares of Johnson & Johnson from $163.00 to $166.00 and gave the stock an "equal weight" rating in a research note on Wednesday, October 16th. Seven analysts have rated the stock with a hold rating and seven have given a buy rating to the company's stock. Based on data from MarketBeat.com, Johnson & Johnson has an average rating of "Moderate Buy" and a consensus target price of $174.29.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.